Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyle A Emmitte

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Chemmedchem|January 24, 2012
Discovery of 2-(2-benzoxazoyl amino)-4-aryl-5-cyanopyrimidine as negative allosteric modulators (NAMs) of metabotropic glutamate receptor 5 (mGlu₅): from an artificial neural network virtual screen to an in vivo tool compoundRalf Mueller, Eric S Dawson, Jens Meiler, et al.
ACS Medicinal Chemistry Letters|March 21, 2019
Discovery of VU2957 (Valiglurax): An mGlu<sub>4</sub> Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's DiseaseJoseph D Panarese, Darren W Engers, Yong-Jin Wu, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 29, 2015
Partial mGlu₅ Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like EffectsRobert W Gould, Russell J Amato, Michael Bubser, et al.
Journal of Medicinal Chemistry|May 23, 2017
Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical EvaluationAndrew S Felts, Alice L Rodriguez, Anna L Blobaum, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 20, 2012
The role of aldehyde oxidase and xanthine oxidase in the biotransformation of a novel negative allosteric modulator of metabotropic glutamate receptor subtype 5Ryan D Morrison, Anna L Blobaum, Frank W Byers, et al.
Bioorganic & Medicinal Chemistry Letters|February 25, 2009
Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein bindingKyle A Emmitte, George M Adjabeng, George M Adjebang, et al.
Bioorganic & Medicinal Chemistry Letters|December 4, 2018
The discovery of VU0652957 (VU2957, Valiglurax): SAR and DMPK challenges en route to an mGlu<sub>4</sub> PAM development candidateJoseph D Panarese, Darren W Engers, Yong-Jin Wu, et al.
Bioorganic & Medicinal Chemistry Letters|May 18, 2016
Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine coreMichael R Wood, Meredith J Noetzel, Julie L Engers, et al.
Bioorganic & Medicinal Chemistry Letters|December 23, 2008
Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R)Kyle A Emmitte, Brian J Wilson, Erich W Baum, et al.
Cell|June 6, 2015
Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule ProbesStuart L Schreiber, Joanne D Kotz, Min Li, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Chemmedchem|January 24, 2012
Discovery of 2-(2-benzoxazoyl amino)-4-aryl-5-cyanopyrimidine as negative allosteric modulators (NAMs) of metabotropic glutamate receptor 5 (mGlu₅): from an artificial neural network virtual screen to an in vivo tool compoundRalf Mueller, Eric S Dawson, Jens Meiler, et al.
ACS Medicinal Chemistry Letters|March 21, 2019
Discovery of VU2957 (Valiglurax): An mGlu<sub>4</sub> Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's DiseaseJoseph D Panarese, Darren W Engers, Yong-Jin Wu, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 29, 2015
Partial mGlu₅ Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like EffectsRobert W Gould, Russell J Amato, Michael Bubser, et al.
Journal of Medicinal Chemistry|May 23, 2017
Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical EvaluationAndrew S Felts, Alice L Rodriguez, Anna L Blobaum, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 20, 2012
The role of aldehyde oxidase and xanthine oxidase in the biotransformation of a novel negative allosteric modulator of metabotropic glutamate receptor subtype 5Ryan D Morrison, Anna L Blobaum, Frank W Byers, et al.
Bioorganic & Medicinal Chemistry Letters|February 25, 2009
Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein bindingKyle A Emmitte, George M Adjabeng, George M Adjebang, et al.
Bioorganic & Medicinal Chemistry Letters|December 4, 2018
The discovery of VU0652957 (VU2957, Valiglurax): SAR and DMPK challenges en route to an mGlu<sub>4</sub> PAM development candidateJoseph D Panarese, Darren W Engers, Yong-Jin Wu, et al.
Bioorganic & Medicinal Chemistry Letters|May 18, 2016
Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine coreMichael R Wood, Meredith J Noetzel, Julie L Engers, et al.
Bioorganic & Medicinal Chemistry Letters|December 23, 2008
Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R)Kyle A Emmitte, Brian J Wilson, Erich W Baum, et al.
Cell|June 6, 2015
Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule ProbesStuart L Schreiber, Joanne D Kotz, Min Li, et al.
Pageof 7